Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(Grazoprevir; MK 5172; MK5172)
MK-5172 Chemical Structure
|Product name: MK-5172|
|Cat. No.: HY-15298|
MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
IC50 Value: 7.4 nM and 7 nM for genotype 1b and 1a respectively, in replicon system 
Target: HCV NS3/4a protease
in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a .
in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose .
Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1
|M.Wt||766.9||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||1.3040 mL||6.5198 mL||13.0395 mL|
|5 mM||0.2608 mL||1.3040 mL||2.6079 mL|
|10 mM||0.1304 mL||0.6520 mL||1.3040 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|MK-5172||Merck & Co Inc||Hepatitis C virus infection||31-JAN-13||30-APR-14||Phase 2||12-SEP-13|
|Merck & Co Inc||Hepatitis C virus infection||28-FEB-13||31-AUG-14||Phase 2||19-NOV-13|
|Merck & Co Inc||Hepatitis C virus infection||31-DEC-12||31-JAN-14||Phase 2||04-NOV-13|
|Merck & Co Inc||Hepatitis C virus infection||31-OCT-13||30-SEP-14||Phase 2||23-OCT-13|
. Summa V, Ludmerer SW, McCauley JA, MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7.
ABT-333 is an NS5B non-nucleoside polymerase inhibitor.
Anguizole is a small molecule inhibitor of HCV replication and alters NS4B(acute)s subcellular distribution.
Artemisinin (NSC 369397), a widely used anti-malarial drug, is an inhibitor of HCV subgenomic replicon replication.
Asunaprevir (BMS-650032) is a potent hepatitis C virus (HCV) NS3 protease inhibitor.
Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479).
Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.
Boceprevir(EBP-520, SCH503034) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection.
Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.
KIN1408 is an antiviral small molecule compound, as agonists of the RLR pathway.
Narlaprevir is a potent, selective, orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM)